David Shaw’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-21,626
| Closed | -$464K | – | 4935 |
|
|
2026
Q1 | $464K | Sell |
21,626
-293
| -1% | -$4.13K | ﹤0.01% | 3888 |
|
|
2025
Q4 | $204K | Sell |
21,919
-56,053
| -72% | -$468K | ﹤0.01% | 4321 |
|
|
2025
Q3 | $550K | Sell |
77,972
-3,331
| -4% | -$22.9K | ﹤0.01% | 3817 |
|
|
2025
Q2 | $528K | Sell |
81,303
-1,767
| -2% | -$12.2K | ﹤0.01% | 3617 |
|
|
2025
Q1 | $659K | Sell |
83,070
-63,315
| -43% | -$682K | ﹤0.01% | 3339 |
|
|
2024
Q4 | $1.85M | Buy |
146,385
+3,250
| +2% | +$45.2K | ﹤0.01% | 2785 |
|
|
2024
Q3 | $1.99M | Sell |
143,135
-81,205
| -36% | -$1.16M | ﹤0.01% | 2721 |
|
|
2024
Q2 | $3.09M | Buy |
224,340
+121
| +0.1% | +$1.77K | ﹤0.01% | 2242 |
|
|
2024
Q1 | $3.7M | Buy |
224,219
+28,730
| +15% | +$430K | ﹤0.01% | 2130 |
|
|
2023
Q4 | $2.85M | Sell |
195,489
-739
| -0.4% | -$8.96K | ﹤0.01% | 2383 |
|
|
2023
Q3 | $2.41M | Sell |
196,228
-17,188
| -8% | -$224K | ﹤0.01% | 2428 |
|
|
2023
Q2 | $2.55M | Sell |
213,416
-210,963
| -50% | -$2.76M | ﹤0.01% | 2434 |
|
|
2023
Q1 | $5.67M | Sell |
424,379
-176,943
| -29% | -$3.46M | 0.01% | 1827 |
|
|
2022
Q4 | $12.9M | Buy |
601,322
+34,174
| +6% | +$701K | 0.01% | 1217 |
|
|
2022
Q3 | $11.4M | Buy |
567,148
+428,830
| +310% | +$9.12M | 0.01% | 1246 |
|
|
2022
Q2 | $2.48M | Buy |
+138,318
| New | +$1.43M | ﹤0.01% | 2883 |
|
|
2022
Q1 | – | Sell |
-13,404
| Closed | -$226K | – | 5606 |
|
|
2021
Q4 | $226K | Buy |
+13,404
| New | +$275K | ﹤0.01% | 4818 |
|
Other funds holding DAWN
David Shaw's DAWN Position: Q2 2026 in Review
David Shaw sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 21,626 shares — an estimated $464K sold.
David Shaw first reported a position in DAWN in Q4 2021 and held it in 17 quarters. The position peaked at $12.9M in Q4 2022. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- David Shaw reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- David Shaw sold 21,626 Day One Biopharmaceuticals shares in Q2 2026, an estimated $464K.
- David Shaw first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 17 quarters.
- David Shaw's Day One Biopharmaceuticals position peaked at $12.9M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.